NCT05009537 Optical Genome Mapping in Hematological Malignancies
| NCT ID | NCT05009537 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Brest |
| Condition | MDS |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-09 |
| Primary Completion | 2022-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2021-09 with a primary completion date of 2022-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
Eligibility Criteria
Inclusion Criteria: * Minor/Major Patients * Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made. * No objection made or consent given Exclusion Criteria: * Patients under judicial protection (guardianship, curatorship, ...), * Refusal to participate
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05009537 clinical trial?
This trial is open to participants of all sexes, studying MDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05009537 currently recruiting?
Yes, NCT05009537 is actively recruiting participants. Contact the research team at Marie-berengere.troadec@chu-brest.fr for enrollment information.
Where is the NCT05009537 trial being conducted?
This trial is being conducted at Brest, France, Morlaix, France, Quimper, France, Saint-Brieuc, France.
Who is sponsoring the NCT05009537 clinical trial?
NCT05009537 is sponsored by University Hospital, Brest. The trial plans to enroll 200 participants.